CingulateCING
Market Cap: $12.9M
About: Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Employees: 13
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
68% more capital invested
Capital invested by funds: $129K [Q1] → $217K (+$88.3K) [Q2]
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
11% more funds holding
Funds holding: 9 [Q1] → 10 (+1) [Q2]
5.1% more ownership
Funds ownership: 4.16% [Q1] → 9.26% (+5.1%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for CING.
Financial journalist opinion
Based on 6 articles about CING published over the past 30 days